IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2].

IMMH001 is metabolized into its active monophosphate ester form, (S)-IMMH001-P, by the action of sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo [1]. This compound effectively diminishes disease manifestations mediated by both Th1 (IL-1β, IL-18, and IP10) and Th2 (IL-5) cells in inflamed joints [2]. Administered orally at doses ranging from 0.3 to 2.4 mg/kg twice weekly for durations of 28 days in adjuvant-induced arthritis (AA) rats and 30 days in collagen-induced arthritis (CIA) rats, IMMH001 significantly alleviates joint damage in these models [2].